Is TAVR Too Common Among Younger Patients? New Data Prompt a ‘Call to Action’

Why It Matters

Overuse of TAVR in younger, lower‑risk patients could expose them to higher long‑term complications and strain payer budgets, while undermining guideline‑driven care standards.

Key Takeaways

• TAVR cases rose from 2,500 (2017) to ~6,000 (2023)
• 36% of patients <65 received TAVR despite guideline preference for SAVR
• One‑year mortality for young TAVR patients reported at 9.9%
• Guidelines advise surgery for most under‑65 aortic valve replacements
• Study calls for stronger heart‑team oversight and new evidence

Pulse Analysis

The rapid diffusion of transcatheter aortic valve replacement has reshaped cardiac care, offering quicker recovery and less invasive implantation compared with traditional surgery. Those advantages have driven clinicians to expand TAVR beyond high‑risk cohorts, especially as device technology from manufacturers like Edwards Lifesciences and Medtronic improves durability. However, the current data set reveals that the enthusiasm may be outpacing evidence, particularly for patients under 65 whose life expectancy and valve longevity concerns differ markedly from older populations.

The Circulation analysis, which merged the ACC/STS TVT Registry with the STS Adult Cardiac Surgery Database, highlights a concerning trend: more than one‑third of younger patients now receive TAVR, yet the one‑year mortality approaches 10%. This figure eclipses outcomes typically seen in surgical cohorts and suggests that inappropriate patient selection could be eroding the perceived safety advantage of the transcatheter route. Heart‑team deliberations—once the cornerstone of valve‑replacement decisions—appear to be sidelined by procedural convenience and hospital throughput pressures, raising red flags for both clinicians and payers.

For the medical device industry, the findings signal a potential regulatory and reimbursement pivot. Payers may tighten coverage criteria for TAVR in low‑risk, younger patients, while the FDA could demand longer‑term durability data before expanding indications. Meanwhile, academic centers are likely to launch prospective trials to clarify outcomes and inform updated guidelines. Stakeholders that adapt quickly—by investing in robust evidence generation and reinforcing multidisciplinary decision pathways—will safeguard patient outcomes and preserve market confidence in transcatheter technologies.